PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Schizophr Res. Author manuscript; available in PMC 2011 March 10.
Published in final edited form as:
PMCID: PMC3052695
NIHMSID: NIHMS277078

The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome

Abstract

The American Psychiatric Association Task Force on DSM-5 has recently proposed consideration of Attenuated Psychotic Symptoms Syndrome as a new diagnosis, based on nearly 15 years of prospective research in centers across the globe. The condition is also known as “psychosis risk syndrome,” “at-risk mental state,” “ultra-high risk,” and “putative prodrome.” We review evidence favoring its inclusion as a new diagnosis in DSM-5 and report new preliminary findings on DSM-IV diagnoses in current clinical use for these patients and on results of diagnostic interviews in unselected volunteers.

The main evidence supporting inclusion is: (1) the patients are currently ill, (2) the patients are at high risk for getting worse, (3) no DSM-IV diagnosis accurately captures their current illness or future risk, (4) the diagnosis has been made with reliability and validity in the research setting, and (5) placement in DSM-5 would help promote the needed treatment and prevention research to enable articulation of a standard of care to benefit these patients and their families. Potential harms can be minimized by patient, family, and provider education. It will be important to demonstrate through well-designed field trials whether the diagnostic criteria can be used with reliability in everyday clinical practice.

Keywords: Risk syndrome, APS syndrome, Psychosis, Early detection, Prevention, DSM-5

1. Attenuated Psychotic Symptoms Syndrome

The Psychosis Workgroup of the American Psychiatric Association (APA) DSM-5 Task Force has been considering a proposal for a psychosis risk syndrome as a new diagnosis (Carpenter, 2009; Heckers, 2009). In February, 2010, APA posted draft criteria invited comment. In May–August the draft criteria were revised based on comments (DSM-5 Task Force, 2010a). The revised draft criteria are shown in the Panel. The new Attenuated Psychotic Symptoms Syndrome, or APS syndrome, nomenclature focuses on the current clinical state and parallels the preferred terminology for the dementia risk syndrome: mild cognitive impairment (Petersen et al., 1999) or minor neurocognitive disorder (DSM-5 Task Force, 2010b).

The primary purpose of this paper is to review published evidence in favor of inclusion of APS syndrome in DSM-5. New preliminary data on DSM-IV diagnoses in current clinical use for these patients and on results of diagnostic interviews in unselected community volunteers are also presented.

2. The proposed DSM-5 criteria

The proposed criteria are more restrictive than both related research criteria sets in current use (Table 1). Specifically, the proposed DSM-5 criteria require that the characteristic attenuated positive symptoms must be associated with distress, disability, and help-seeking (Panel). The requirement for distress arises from studies suggesting that recruited patients whose distress arises not from attenuated positive symptoms but from other complaints may be at low risk of conversion (Section 4). The requirement for disability arises from a comparison of 6 large studies (Addington et al., 2010; Cannon et al., 2008; Mason et al., 2004; Ruhrmann et al., 2010b; Yung et al., 2004b; Yung et al., 2006b), all of which found that low functioning is associated with higher conversion rates. The requirement for help-seeking is derived from epidemiologic studies suggesting high prevalence of psychotic-like symptoms (Eaton et al., 1991; Hanssen et al., 2005; Rossler et al., 2007; Tien, 1991; van Os et al., 2000; van Os et al., 2009; Yung et al., 2006a) and a low rate of conversion to psychosis (Hanssen et al., 2005; Rossler et al., 2007) among persons with no need for care.

Table 1
Comparison of proposed DSM-5 for APS syndrome and research criteria.

In addition, criteria B and C (Panel) are absent in one set of research criteria (Table 1). Epidemiologic evidence suggests that psychotic-like experiences that do not persist (present in past month) are unlikely to lead to frank psychosis (Dominguez et al., 2009). The help-seeking control group in the NAPLS validity study demonstrates that, among nonschizotypal patients, attenuated positive symptoms that have been longstanding and stable rather than recently progressive (criterion C) are also unlikely to lead to frank psychosis (Woods et al., 2009).

Since the proposed DSM-5 criteria are more restrictive than currently employed research criteria, the DSM-5 criteria are likely to identify patients at higher risk of conversion to psychosis and to exclude more false positive patients than the research criteria.

3. APS syndrome patients are currently ill

Individuals meeting the more restrictive DSM-5 criteria may still be true positives or false positives for conversion to psychosis, but no person meeting APS syndrome criteria is a false positive for current illness. APS patients are symptomatic, functionally impaired, and treatment-seeking. These features alone seem sufficient for a new diagnosis.

3.1. APS syndrome patients are symptomatic

APS patients have positive symptoms, negative symptoms, disorganization symptoms, and nonspecific general symptoms such as depressed and anxious mood (Hawkins et al., 2004b; Woods et al., 2009). Two early studies demonstrated that untreated APS patients had more severe positive symptoms than treated first episode psychosis patients (Miller et al., 2003b; Yung et al., 1996). Depressive and manic symptoms were less severe than in adolescent depression and mania samples (Miller et al., 2003b).

3.2. APS syndrome patients are functionally impaired

Representative early studies found baseline current Global Assessment of Functioning (GAF) scores for APS patients in the 40s (serious impairment) (Miller et al., 2003b) and 50s (moderate impairment) (Mason et al., 2004; Yung et al., 1998). Recent studies using more specific measures confirm current impairments of social and/or role functioning (Addington et al., 2008; Ballon et al., 2007; Shim et al., 2008).

3.3. APS syndrome patients as a group are cognitively impaired

Most studies find that at-risk patients are more cognitively impaired than controls (Table 2).

Table 2
Studies of cognitive functioning in APS syndrome patients vs controls.

3.4. Many APS syndrome patients are help-seeking

Although epidemiologic studies are lacking, several reports document that at least some at-risk patients are help-seeking (Amminger et al., 2010; McGlashan et al., 2007; McGlashan et al., 2006; McGorry et al., 2002a; Morrison et al., 2004; Preda et al., 2002; Walker et al., 2009; Woods et al., 2003; Woods et al., 2007). As noted above, the proposed DSM-5 criteria require help-seeking.

4. APS syndrome patients are at high risk for getting worse

In the large NAPLS cohort (at-risk n=303), Kaplan–Meier analyses show that 40% of at-risk patients converted to fully psychotic illness during 2.5 years of follow-up (Woods et al., 2009). Many patients who do not convert continue to be symptomatic (Woods, 2010).

In the next largest cohort, the recent European Prediction of Psychosis (EPOS) study, conversion rates among APS disorder-type patients were lower: around 20% at 1.5 years (Ruhrmann et al., 2010b). In both NAPLS and EPOS, the conversion rates may have been reduced by treatment received during naturalistic follow-up. In NAPLS, among subjects not enrolled in clinical trials, 25% received antipsychotics (Walker et al., 2009), and at least 13% in EPOS (Ruhrmann et al., 2010b). Since both studies report that subjects prescribed antipsychotics were more symptomatic at baseline, the possibility exists that the highest-risk subjects in the cohorts were selected for antipsychotic treatment, which then had a beneficial effect (McGlashan et al., 2006; McGorry et al., 2002b; Ruhrmann et al., 2007; Woods et al., 2003; Woods et al., 2007) that lowered their risk.

Although in both NAPLS and EPOS cohorts the conversion rate decelerated across the follow-up interval, the possibility still exists that more patients would have converted with longer follow-up. With an alternate conception of the at-risk syndrome that overlaps considerably with the APS-like conception in the EPOS sample (Ruhrmann et al., 2010b), the conversion rate was 70% over a mean 9.6 year follow-up (Klosterkotter et al., 2001).

In the past few years, the site that originally described the at-risk syndrome (Yung et al., 1996) has reported a declining rate of conversion to psychosis (Yung et al., 2008; Yung et al., 2007). Interpretation has emphasized the possible role of sample dilution via referral of subjects whose attenuated positive symptoms were not associated with help seeking but were only incidental to help seeking behavior associated with other psychiatric syndromes. This experience contributed to the inclusion of criterion D (Panel), where the attenuated positive symptoms themselves must be associated with distress, disability, and help-seeking, so that the proposed DSM-5 criteria should not permit the low risk patients diluting the samples in these reports to receive the diagnosis.

One concern about proposing an APS syndrome diagnosis is that it will be abused by using the criteria to screen general populations. Without criterion D, this practice would be likely to yield low rates of conversion among the screened cases and thus should probably be conducted only very cautiously (Woods et al., 2010). We agree, however, with McGorry that potential for misuse is an insufficient argument against inclusion of a new diagnosis (McGorry, 2010).

Another concern about the APS syndrome is that the most common risk outcome is said to be persistence or emergence of nonpsychotic affective or anxiety disorders (McGorry, 2010). Our field has still not clarified this issue, but it seems that the large majority of nonpsychotic affective or anxiety disorders outcomes are not newly emergent incident outcomes but rather are cases of persistence of comorbid symptoms previously present at baseline (e.g. being “at risk” for something that was already there). Assuming that future data presentations bear out this impression, then among the newly emergent disorders psychosis should be quite specific (Woods et al., 2010). Baseline anxiety and affective disorders are very common not only among patients meeting APS criteria, but also among patients who seek an at-risk structured interview but do not meet criteria (Woods et al., 2009). This last group of anxious and depressed young people who do not have qualifying attenuated positive symptoms do not convert to psychosis at appreciable rates (Woods et al., 2009).

5. No DSM-IV diagnosis accurately captures these patients

APS syndrome patients currently seek help in our health care systems, and they are given a variety of DSM-IV diagnoses clinically. As there is little or no specific evidence on this point available in the literature, we conducted a survey on 14 consecutive patients meeting SIPS criteria referred to our research clinic February through March 2010 from providers who had billed third party payers for their clinical evaluation. We asked about the provider’s background, the specific DSM-IV diagnoses used for billing purposes, and whether the provider was satisfied with the DSM-IV diagnoses.

Table 3 shows the results. Ten different diagnoses were given; the more frequent included psychotic disorder NOS (n=4) and attention-deficit/hyperactivity disorder (n=2). Of the 14 surveyed providers, 13 indicated that they were not satisfied with these diagnoses. Edited provider comments are shown.

Table 3
DSM-IV billing diagnoses prior to APS syndrome research referral.

These data do demonstrate that clinicians can select DSM-IV diagnoses for APS syndrome patients when required do so for reimbursement. However, the data also show that clinicians are not satisfied that DSM-IV accurately captures the clinical picture with these patients. Consistent with this dissatisfaction, review of DSM-IV indicates that attenuated positive symptoms are not mentioned in the text describing any disorder in Table 3.

6. Reliability and validity

6.1. APS syndrome may be diagnosed with validity in research settings

Two large studies have demonstrated statistically significant predictive validity of an at-risk diagnosis compared to help-seeking controls (Woods et al., 2009; Yung et al., 2008). Since help-seeking controls are patients referred for at-risk research evaluation who did not meet criteria, they constitute the optimal ecologically valid control group. In one study, 88 of 303 SIPS-diagnosed patients (29%, 40% using Kaplan Meier methods that adjust for loss to follow-up) developed frank psychosis over up to 2.5 years, while only 3 of 135 (2%, 4% by Kaplan–Meier) help-seeking controls converted (p < 0.001). In the other study, 19 of 119 CAARMS-diagnosed patients (12%) developed frank psychosis over 6 months, while only 2 of 173 (1%) help-seeking controls converted (p < 0.001).

6.2. APS syndrome may be diagnosed and rated with reliability in research settings

One structured interview has shown excellent diagnostic interrater reliability across eleven sites (Addington et al., 2007; Miller et al., 2003a Miller et al., 2002). Reliability for severity of the characteristic positive symptoms has also been excellent (Lencz et al., 2003; Miller et al., 2003a; Yung et al., 2005).

Before APS syndrome could be accepted as a DSM-5 diagnosis, well-designed field trials would need to demonstrate that the diagnosis is reliable not just in the research setting but also under ordinary clinical conditions.

6.3. Prevalence of APS syndrome among community-dwelling young people

One concern about the proposed DSM-5 APS syndrome diagnosis is the perception that large numbers of seemingly healthy young people would qualify (First, 2010; Shorter, 2010). This concern would seem valid given the frequent endorsement of psychotic-like experiences on self-report (Section 2). On closer inspection, however, the proportion of community-dwelling young people whose psychotic-like experiences would actually qualify for an APS syndrome diagnosis on psychiatric interview constitutes an unaddressed empirical question. We thus conducted a preliminary study in February–March 2010.

An on-line advertisement was placed in the “volunteers” section of a popular website (Craig’s List New Haven). The advertisement invited young people to participate in a paid study, but by design did not stipulate that subjects needed to be healthy. The only exclusion criteria were psychiatric medication or a family history of schizophrenia. Thirty young people aged 25±3 years responded to the advertisement and underwent SIPS interview without any further screening.

One subject met SIPS criteria (3.3%, 95% confidence interval 0.1 to 17.2%). This subject was actually seeking help for his symptoms, but didn’t know how to find it. Seventeen other subjects scored nonzero scores on one or more positive symptoms; however, in all these cases the scores were below APS syndrome range (Fig. 1).

Fig. 1
Highest SIPS positive symptom score among 30 community volunteers. On the positive symptom scales, the normal range is 0–2, the APS syndrome range 3–5, and frank psychosis 6.

The sample size is small and the confidence intervals are wide, but the data do suggest both that psychotic-like symptoms are common in young people and that they usually are not sufficiently severe to meet diagnostic criteria on interview. Thus a deluge of misdiagnosis with the APS syndrome seems unlikely, even based on consideration of attenuated positive symptoms alone. Moreover, as articulated above, the proposed criteria require distress, disability, and treatment seeking as well.

As Carpenter has pointed out (Carpenter, 2009), the APS syndrome is not unique among psychiatric disorders in being based on behaviors that are on a continuum of human experience. Anxiety, depression, and attention and memory disturbances are similar in this regard. The general requirement in DSM that such disorders be characterized by distress or disability (American Psychiatric Association, 1994), is specifically emphasized in the APS syndrome criteria (Panel).

7. Stigma can be managed and minimized

The possibility that patients diagnosed with an APS syndrome will be stigmatized constitutes an important risk that we do not mean to underestimate. Stigma, either internalized “self-stigma” or social stigma from peers, family, or others, can occur with any psychiatric disorder in adults. Less empirical data is available for young patients, but adolescents receiving intensive care at one service have been reported to experience some stigma associated with their mental illnesses, psychiatric treatment, or psychiatric diagnosis (Moses, 2009a, b, 2010). We have as yet no similar reports in APS syndrome youth, with the exception of a small study showing that family members of at-risk patients endorsed feeling little stigma themselves as a consequence of being related to an at-risk patient (Wong et al., 2009). Despite the current dearth of empirical data, it is likely that future research will show that risk syndrome patients do experience some stigma (Yang et al., 2010). However, there are several reasons to believe the likelihood of stigma does not outweigh the potential benefit of the diagnosis.

First, harm from stigma that does occur for false positives can potentially be reversed. If no APS syndrome diagnosis is made, and patients develop chronic psychosis, stigma is potentially lifelong.

Second, stigma associated with an APS syndrome diagnosis is manageable. We do not consider it ethically unacceptable to enroll subjects in at-risk research clinics. That is because our research clinics intervene to reduce stigma in every case (Yung et al., 2010), by empathically counseling patients and their families on what it means to be at-risk and how being at-risk differs from actually being psychotic. Psychiatric clinicians can do the same.

Lastly, APS syndrome patients are already receiving DSM-IV diagnoses in the community (Table 3), and it is not immediately apparent that an APS syndrome diagnosis is more stigmatizing than psychotic disorder NOS or the other DSM-IV diagnoses currently being given to these patients.

8. Promoting needed treatment and prevention research

Patients who qualify for an APS syndrome diagnosis are in need both of evidence-based treatment for their current symptoms and of evidence-based preventive interventions for their risk of further decline (Ruhrmann et al., 2010a; Woods et al., 2001). However, current practice guidelines are relatively sparse on specific suggestions (Table 4).

Table 4
Published practice guideline recommendations for APS syndrome patients.

The reason that guidelines are relatively sparse in this area is that the evidence itself is sparse. Since 1996, only four modest randomized studies have been published: three of them evaluating medications and two of them cognitive-behavioral therapy (Amminger et al., 2010 McGlashan et al., 2006; McGorry et al., 2002a Morrison et al., 2004).

It might be argued that that APS syndrome is premature to include in DSM-5 if the treatment evidence base is still so thin. However, the DSM is not a therapeutic manual, and the availability of effective treatment is not ordinarily required for a disorder to be included. Moreover, we believe that inclusion in DSM-5 would help to stimulate the conduct of the informative trials that we need, both for psychosocial therapies and for medications.

8.1. The process for large, informative medication treatment studies

In the U.S., large, informative studies of medication treatments are usually funded by pharmaceutical companies. These companies are generally reluctant to fund large studies unless they can legally use the results to promote their products. Medications may not be promoted legally in the U.S. without FDA approval that the medication is reasonably safe and effective for the indication being promoted. Thus the rate-limiting step to generate large, informative treatment studies in the U.S. is an FDA indication. The absence of an FDA indication is one reason why we have so few trials for APS disorder and why the sample sizes are so modest. Although there is no requirement for a disorder to be recorded in the DSM to receive an FDA indication, in our view placement in DSM-5 is likely to facilitate the process.

8.2. The process for development of new, specific medication treatments

The optimal medication treatment for APS would have few or no adverse effects and would be effective, specifically so for this early stage of the disorder and perhaps less so for later stages. A recent trial offers preliminary proof of this concept, reporting that 12 weeks of fish oil treatment might by itself, without any antipsychotic medication, protect APS syndrome patients from becoming psychotic for at least 12 months (Amminger et al., 2010), when findings in chronic patients are inconclusive (Irving et al., 2006). This treatment was studied without a goal of an FDA indication; however, such a pathway to wide use of a new treatment is unusual. Our concern is that without a DSM diagnosis supporting an FDA indication, Phase II programs for other promising new medications specifically for the APS syndrome may never to be launched.

8.3. An APS syndrome diagnosis should reduce inappropriate prescribing

An important concern about the APS syndrome proposal is that it will lead to unnecessary exposure to (Corcoran et al., 2010), and commonplace prescription of (Yung et al., 2010), antipsychotic medications. We agree with Carpenter (Carpenter, 2009) that such practice would not be evidence-based and would do harm. Broadened use of antipsychotics medication has occurred among children and adolescents in recent years (Crystal et al., 2009) across a wide variety of diagnostic classes; thus this concern is not unique to APS syndrome. Moreover, our own view is that inclusion of an APS syndrome diagnosis in DSM-5 should reduce inappropriate prescribing.

First, including an APS syndrome diagnosis in DSM-5 enriches the differential diagnosis, which should help prescribing be more appropriate. The patient with attenuated positive symptoms who receives a DSM-5 APS syndrome diagnosis may be less likely to be prescribed antipsychotics than if that same patient receives a DSM-IV diagnosis of psychotic disorder NOS.

Second, prescribers may now give antipsychotics in the mistaken belief that they are prescribing for APS syndrome patients when the patients do not meet APS syndrome criteria, because clinicians do not have the ready access to the criteria and accompanying text that publication in DSM provides.

Third, inappropriate prescribing is enabled by the paucity of the treatment evidence base. Providers are forced to make decisions based almost solely on clinical judgment.

Lastly, if a DSM-5 diagnosis helps promote specific new therapies for APS syndrome patients, these developments ought to reduce overprescription of antipsychotics.

8.4. The APS syndrome diagnosis as a stage of schizophrenia and related disorders

Clinical staging, akin to staging of neoplastic conditions, has been advocated for psychiatric disorders (McGorry, 2007; Tandon et al., 2009). An evidence-based system of clinical staging would clearly provide a conceptual framework for pathophysiologic studies of progression of disease and therapeutic studies of prevention of progression. In order to reduce a proposed system of staging to practice, operational criteria for each stage of each disorder must be articulated, refined, and tested prospectively for reliability and validity. The current paper argues that these necessary steps have been achieved for the APS syndrome over the past 15 years. APS syndrome then fits into the proposed staging model (McGorry, 2007) as stage 1b of schizophrenia and related psychotic disorders.

9. DSM-5 or DSM-IV?

The alternatives about inclusion of an APS syndrome diagnosis in DSM-5 should not be posed as yes vs no. The question should be posed thus: Which is better for patients and their families—an APS syndrome diagnosis in DSM-5 or sticking with DSM-IV? As we have outlined above, APS syndrome patients are symptomatic and functionally impaired, and no DSM-IV diagnosis accurately captures their suffering. DSM-IV diagnoses are no less stigmatizing and no less in need of empathic management to reduce stigma. DSM-IV has not served to facilitate the generation of treatment research evidence in this area or to prevent inappropriate prescribing. DSM-IV is simply outdated and deficient for this diagnosis, and research documenting the reliability and validity of the APS syndrome over the last decade should enable us to redress this deficiency to the benefit of our patients and their families.

Panel
Revised proposed DSM-5 criteria for APS syndrome.

Acknowledgments

Role of the funding source

This work was supported by Yale University Department of Psychiatry funds. Yale had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Footnotes

Contributors

Author SWW designed the new data collection and wrote the first draft of the manuscript. All authors contributed to and have approved the final report.

Conflict of interest

Drs. Woods and McGlashan are advisors to the Psychosis Work Group of the American Psychiatric Association DSM-5 Task Force. All authors declare that they have no other conflicts of interest.

References

  • Addington D, Bouchard RH, Goldberg J, Honer B, Malla A, Norman R, Tempier R, Berzins S. Clinical practice guidelines — treatment of schizophrenia — special issues. Can J Psychiatry. 2005a;50 (suppl 1):43S.
  • Addington J, Amminger GP, Barbato A, Catts S, Chen E, Chhim S, Chong SA, Cullberg J, Edwards J, Grosso L, Louza M, Hambrecht M, Keshavan M, Johannessen JO, Johnson DL, Lewis S, Lieberman J, MacEwan W, Malla A, May R, McGlashan TH, McGorry P, Merlo MG, Nordentoft M, Nightingale S, Perkins D, Thara R, Yamamoto K, Yung A. International clinical practice guidelines for early psychosis. Brit J Psychiatry. 2005b;187 (Suppl 48):s120–s124.
  • Addington J, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan TH, Perkins DO, Seidman LJ, Tsuang M, Walker EF, Woods SW, Heinssen R. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull. 2007;33 (3):665–672. [PMC free article] [PubMed]
  • Addington J, Penn D, Woods SW, Addington D, Perkins DO. Social functioning in individuals at clinical high risk for psychosis. Schizophr Res. 2008;99 (1–3):119–124. [PMC free article] [PubMed]
  • Addington J, Perkins DO, Woods SW. The PREDICT study. 2010. unpublished data.
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4. Washington, D.C: 1994. p. xxi.
  • Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67 (2):146–154. [PubMed]
  • Ballon JS, Kaur T, Marks II, Cadenhead KS. Social functioning in young people at risk for schizophrenia. Psychiatry Res. 2007;151 (1–2):29–35. [PMC free article] [PubMed]
  • Bartok E, Berecz R, Glaub T, Degrell I. Cognitive functions in prepsychotic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29 (4):621–625. [PubMed]
  • Becker HE, Nieman DH, Dingemans PM, van de Fliert JR, De Haan L, Linszen DH. Verbal fluency as a possible predictor for psychosis. Eur Psychiatry. 2010;25 (2):105–110. [PubMed]
  • Brewer WJ, Wood SJ, McGorry PD, Francey SM, Phillips LJ, Yung AR, Anderson V, Copolov DL, Singh B, Velakoulis D, Pantelis C. Impairment of olfactory identification ability in individuals at ultra-high risk for psychosis who later develop schizophrenia. Am J Psychiatry. 2003;160 (10):1790–1794. [PubMed]
  • Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, Yung AR, Anderson VA, McGorry PD. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry. 2005;162 (1):71–78. [PubMed]
  • Broome MR, Matthiasson P, Fusar-Poli P, Woolley JB, Johns LC, Tabraham P, Bramon E, Valmaggia L, Williams SCR, Brammer MJ, Chitnis X, McGuire PK. Neural correlates of executive function and working memory in the ‘at-risk mental state’ Brit J Psychiatry. 2009;194 (1):25–33. [PubMed]
  • Cannon TD, Cadenhead KS, Cornblatt B, Woods SW, Addington J, Walker EF, Seidman LJ, Perkins DO, Tsuang M, McGlashan TH, Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65 (1):28–37. [PMC free article] [PubMed]
  • Carpenter WT. Anticipating DSM-V: should psychosis risk become a diagnostic class? Schizophr Bull. 2009;35 (5):841–843. [PMC free article] [PubMed]
  • Corcoran CM, First MB, Cornblatt B. The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk–benefit analysis. Schizophr Res. 2010;120 (1–3):16–22. [PMC free article] [PubMed]
  • Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood) 2009;28 (5):w770–w781. [PMC free article] [PubMed]
  • De Masi S, Sampaolo L, Mele A, Morciano C, Cappello S, Meneghelli A, de Girolamo G. The Italian guidelines for early intervention in schizophrenia: development and conclusions. Early Interv Psychiatry. 2008;2 (4):291–302. [PubMed]
  • Dominguez MD, Wichers M, Lieb R, Wittchen HU, van Os J. Evidence that onset of clinical psychosis is an outcome of progressively more persistent subclinical psychotic experiences: An 8-year cohort study. Schizophr Bull. 2009 advanced acees published May 21, 2009. [PMC free article] [PubMed]
  • Proposed draft revisions to DSM disorders and criteria: Minor neurocognitive disorder. American Psychiatric Association; [accessed July 30, 2010]. http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid=420.
  • DSM-5 Task Force. Proposed draft revisions to DSM disorders and criteria: attenuated psychotic symptoms syndrome. American Psychiatric Association; 2010.
  • Eastvold AD, Heaton RK, Cadenhead KS. Neurocognitive deficits in the (putative) prodrome and first episode of psychosis. Schizophr Res. 2007;93 (1–3):266–277. [PMC free article] [PubMed]
  • Eaton WW, Romanoski A, Anthony JC, Nestadt G. Screening for psychosis in the general population with a self-report interview. J Nerv Ment Dis. 1991;179 (11):689–693. [PubMed]
  • First M. Revising Book on Disorders of the Mind. The New York Times; New York: 2010. quoted in Carey, B.
  • Francey SM, Jackson HJ, Phillips LJ, Wood SJ, Yung AR, McGorry PD. Sustained attention in young people at high risk of psychosis does not predict transition to psychosis. Schizophr Res. 2005;79 (1):127–136. [PubMed]
  • Gschwandtner U, Aston J, Borgwardt S, Drewe M, Feinendegen C, Lacher D, Lanzarone A, Stieglitz RD, Riecher-Rossler A, Gediga G, Schottke H, Hansgen KD, Zimmermann P, Fimm B. Neuropsychological and neurophysiological findings in individuals suspected to be at risk for schizophrenia: preliminary results from the Basel early detection of psychosis study — Fruherkennung von Psychosen (FEPSY) Acta Psychiatr Scand. 2003;108 (2):152–155. [PubMed]
  • Gschwandtner U, Pfluger M, Aston J, Borgwardt S, Drewe M, Stieglitz RD, Riecher-Rossler A. Fine motor function and neuropsychological deficits in individuals at risk for schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2006;256 (4):201–206. [PubMed]
  • Hambrecht M, Lammertink M, Klosterkotter J, Matuschek E, Pukrop R. Subjective and objective neuropsychological abnormalities in a psychosis prodrome clinic. Brit J Psychiatry — Supplementum. 2002;43:30–37. [PubMed]
  • Hanssen M, Bak M, Bijl R, Vollebergh W, van Os J. The incidence and outcome of subclinical psychotic experiences in the general population. Brit J Clin Psychol. 2005;44 (Pt 2):181–191. [PubMed]
  • Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipurksy R, Woods SW, Miller TJ, Marquez E, Breier A, McGlashan TH. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr Res. 2004a;67 (2–3):115–122. [PubMed]
  • Hawkins KA, McGlashan TH, Quinlan D, Miller TJ, Perkins DO, Zipursky RB, Addington J, Woods SW. Factorial structure of the Scale of Prodromal Symptoms. Schizophr Res. 2004b;68 (2–3):339–347. [PubMed]
  • Heckers S. Who is at risk for a psychotic disorder? Schizophr Bull. 2009;35 (5):847–850. [PMC free article] [PubMed]
  • Irving CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev. 2006. [accessed August 3, 2010]. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16855961. [PubMed]
  • Keefe RSE, Perkins DO, Gu H, Zipursky RB, Christensen BK, Lieberman JA. A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr Res. 2006;88 (1–3):26–35. [PubMed]
  • Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58 (2):158–164. [PubMed]
  • Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, McIntyre JS, Charles SC, Altshuler K, Cook I, Cross CD, Mellman L, Moench LA, Norquist G, Twemlow SW, Woods S, Yager J. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl S):1–56. [PubMed]
  • Lencz T, Smith CW, Auther AM, Correll CU, Cornblatt BA. The assessment of “prodromal schizophrenia”: unresolved issues and future directions. Schizophr Bull. 2003;29 (4):717–728. [PubMed]
  • Lencz T, Smith CW, McLaughlin D, Auther A, Nakayama E, Hovey L, Cornblatt BA. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry. 2006;59 (9):863–871. [PubMed]
  • Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first episode psychosis among individuals with ‘at-risk mental states’ Schizophr Res. 2004;71 (2–3):227–237. [PubMed]
  • McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163 (5):790–799. [PubMed]
  • McGlashan TH, Addington J, Cannon T, Heinimaa M, McGorry P, O’Brien M, Penn D, Perkins D, Salokangas RK, Walsh B, Woods SW, Yung A. Recruitment and treatment practices for help-seeking “pro-dromal” patients. Schizophr Bull. 2007;33 (3):715–726. [PMC free article] [PubMed]
  • McGlashan TH, Walsh BC, Woods SW. The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-up. Oxford University Press; New York: 2010.
  • McGorry PD. Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. Am J Psychiatry. 2007;164 (6):859–860. [PubMed]
  • McGorry PD. Risk syndromes, clinical staging and DSM V: new diagnostic infrastructure for early intervention in psychiatry. Schizophr Res. 2010;120 (1–3):49–53. [PubMed]
  • McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002a;59 (10):921–928. [PubMed]
  • McGorry PD, Yung AF, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, Adlard S, McDonald T, Blair A, Adlard S, Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002b;59:921–928. [PubMed]
  • McGorry P, Killackey E, Lambert T, Lambert M, Jackson H, Codyre D, James N, Pantelis C, Pirkis J, Jones P, Durie MA, McGrath J, McGlashan T, Malla A, Farhall J, Hermann H, Hocking B. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Austral N Z J Psychiatry. 2005;39 (1–2):1–30.
  • Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, Woods SW. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159 (5):863–865. [PubMed]
  • Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003a;29 (4):703–715. [PubMed]
  • Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Marquez E, Tohen M, Breier A, McGlashan TH. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the “prodromal” sample. Schizophr Res. 2003b;61 (1):19–30. [PubMed]
  • Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parker S, Bentall RP. Cognitive therapy for the prevention of psychosis in people at ultra-high risk. Randomized controlled trial. Brit J Psychiatry. 2004;185:291–297. [PubMed]
  • Moses T. Self-labeling and its effects among adolescents diagnosed with mental disorders. Soc Sci Med. 2009a;68 (3):570–578. [PubMed]
  • Moses T. Stigma and self-concept among adolescents receiving mental health treatment. Am J Orthopsychiatry. 2009b;79 (2):261–274. [PubMed]
  • Moses T. Being treated differently: stigma experiences with family, peers, and school staff among adolescents with mental health disorders. Soc Sci Med. 2010;70 (7):985–993. [PubMed]
  • Myles-Worsley M, Ord LM, Ngiralmau H, Weaver S, Blailes F, Faraone SV. The Palau Early Psychosis Study: neurocognitive functioning in high-risk adolescents. Schizophr Res. 2007;89 (1–3):299–307. [PubMed]
  • Niendam TA, Bearden CE, Johnson JK, McKinley M, Loewy R, O’Brien M, Nuechterlein KH, Green MF, Cannon TD. Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr Res. 2006;84 (1):100–111. [PubMed]
  • Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment — clinical characterization and outcome. Arch Neurology. 1999;56 (3):303–308. [PubMed]
  • Pflueger MO, Gschwandtner U, Stieglitz RD, Riecher-Rossler A. Neuropsychological deficits in individuals with an at risk mental state for psychosis — working memory as a potential trait marker. Schizophr Res. 2007;97 (1–3):14–24. [PubMed]
  • Preda A, Miller TJ, Rosen JL, Somjee L, McGlashan TH, Woods SW. Treatment histories of patients with a syndrome putatively prodromal to schizophrenia. Psychiatr Serv. 2002;53 (3):342–344. [PubMed]
  • Pukrop R, Schultze-Lutter F, Ruhrmann S, Brockhaus-Dumke A, Tendolkar I, Bechdolf A, Matuschek E, Klosterkotter J. Neurocognitive functioning in subjects at risk for a first episode of psychosis compared with first- and multiple-episode schizophrenia. J Clin Exp Neuropsychology. 2006;28 (8):1388–1407. [PubMed]
  • Pukrop R, Ruhrmann S, Schultze-Lutter F, Bechdolf A, Brockhaus-Dumke A, Klosterkotter J. Neurocognitive indicators for a conversion to psychosis: comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis. Schizophr Res. 2007;92 (1–3):116–125. [PubMed]
  • Rossler W, Riecher-Rossler A, Angst J, Murray R, Gamma A, Eich D, van Os J, Gross VA. Psychotic experiences in the general population: a twenty-year prospective community study. Schizophr Res. 2007;92 (1–3):1–14. [PubMed]
  • Ruhrmann S, Bechdolf A, Kuhn KU, Wagner M, Schultze-Lutter F, Janssen B, Maurer K, Hafner H, Gaebel W, Moller HJ, Maier W, Klosterkotter J. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Brit J Psychiatry Supplementum. 2007;51:s88–95. [PubMed]
  • Ruhrmann S, Schultze-Lutter F, Klosterkotter J. Probably at-risk, but certainly ill—advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res. 2010a;120 (1–3):23–37. [PubMed]
  • Ruhrmann S, Schultze-Lutter F, Salokangas RKR, Heinimaa M, Linszen D, Dingemans P, Birchwood M, Patterson P, Juckel G, Heniz A, Morrison A, Lewis S, Graf von Reventlow H, Klosterkotter J. Prediction of psychosis in adolescents and adults at high risk: results from the Prospective European Prediction of Psychosis Study. Arch Gen Psychiatry. 2010b;67 (3):241–251. [PubMed]
  • Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, Hawkins K, Heaton R, Keefe RS, Heinssen R, Cornblatt BA. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry. 2010;67 (6):578–588. [PMC free article] [PubMed]
  • Shim G, Kang DH, Chung YS, Yoo SY, Shin NY, Kwon JS. Social functioning deficits in young people at risk for schizophrenia. Austral N Z J Psychiatry. 2008;42 (8):678–685. [PubMed]
  • Shorter E. Why Psychiatry Needs Therapy. Wall Street Journal; New York: 2010.
  • Silverstein S, Uhlhaas PJ, Essex B, Halpin S, Schall U, Carr V. Perceptual organization in first episode schizophrenia and ultra-high-risk states. Schizophr Res. 2006;83 (1):41–52. [PubMed]
  • Simon AE, Cattapan-Ludewig K, Zmilacher S, Arbach D, Gruber K, Dvorsky DN, Roth B, Isler E, Zimmer A, Umbricht D. Cognitive functioning in the schizophrenia prodrome. Schizophr Bull. 2007;33 (3):761–771. [PMC free article] [PubMed]
  • Smith CW, Park S, Cornblatt B. Spatial working memory deficits in adolescents at clinical high risk for schizophrenia. Schizophr Res. 2006;81 (2–3):211–215. [PubMed]
  • Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res. 2009;110 (1–3):1–23. [PubMed]
  • Tien AY. Distributions of hallucinations in the population. Soc Psychiatry Psychiatr Epidem. 1991;26 (6):287–292. [PubMed]
  • van Os J, Hanssen M, Bijl RV, Ravelli A. Strauss (1969) revisited: a psychosis continuum in the general population? Schizophr Res. 2000;45 (1–2):11–20. [PubMed]
  • van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med. 2009;39:179–195. [PubMed]
  • Walker EF, Cornblatt BA, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Woods SW, Heinssen R. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr Res. 2009;115 (1):50–57. [PMC free article] [PubMed]
  • Wong C, Davidson L, Anglin D, Link B, Gerson R, Malaspina D, McGlashan T, Corcoran C. Stigma in families of individuals in early stages of psychotic illness: family stigma and early psychosis. Early Interv Psychiatry. 2009;3 (2):108–115. [PMC free article] [PubMed]
  • Wood SJ, Pantelis C, Proffitt T, Phillips LJ, Stuart GW, Buchanan JA, Mahony K, Brewer W, Smith DJ, McGorry PD. Spatial working memory ability is a marker of risk-for-psychosis. Psychol Med. 2003;33 (7):1239–1247. [PubMed]
  • Woods SW. DSM-V debate: DSM-V needs a psychosis risk syndrome. Schizophrenia International Research Society Meeting; Florence. April 11.2010.
  • Woods SW, Carlson JP, McGlashan TH. DSM-5 and the ‘Psychosis Risk Syndrome’: The DSM-5 proposal is better than DSM-IV. Psychosis. 2010;2:187–190. [PMC free article] [PubMed]
  • Woods SW, Miller TJ, McGlashan TH. The “prodromal” patient: both symptomatic and at-risk. CNS Spectr. 2001;6 (3):223–232. [PubMed]
  • Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry. 2003;54 (4):453–464. [PubMed]
  • Woods SW, Tully EM, Walsh BC, Hawkins KA, Callahan JL, Cohen SJ, Mathalon DH, Miller TJ, McGlashan TH. Aripiprazole in the treatment of the psychosis prodrome: an open label pilot study. Brit J Psychiatry. 2007;191 (suppl 51):s96–s101. [PubMed]
  • Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Validity of the prodromal risk syndrome for psychosis: findings from North American Prodrome Longitudinal Study. Schizophr Bull. 2009;35:894–908. [PMC free article] [PubMed]
  • Yang LH, Wonpat-Borja AJ, Opler MG, Corcoran CM. Potential stigma associated with inclusion of the psychosis risk syndrome in the DSM-V: an empirical question. Schizophr Res. 2010;120 (1–3):42–48. [PMC free article] [PubMed]
  • Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull. 1996;22 (2):283–303. [PubMed]
  • Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, Harrigan S, Patton GC, Jackson HJ. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Brit J Psychiatry. 1998;172(33 Suppl):14–20. [PubMed]
  • Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004a;67 (2–3):131–142. [PubMed]
  • Yung A, Phillips L, McGorry PD. Treating Schizophrenia in the Prodromal Phase. Taylor & Francis; London: 2004b.
  • Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell’Olio M, Francey SM, Cosgrave EM, Killackey E, Stanford C, Godfrey K, Buckby J. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Austral N Z J Psychiatry. 2005;39 (11–12):964–971. [PubMed]
  • Yung AR, Buckby JA, Cotton SM, Cosgrave EM, Killackey EJ, Stanford C, Godfrey K, McGorry PD. Psychotic-like experiences in nonpsychotic help-seekers: associations with distress, depression, and disability. Schizophr Bull. 2006a;32 (2):352–359. [PMC free article] [PubMed]
  • Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B, McGorry PD. Testing the ultra high risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res. 2006b;84 (1):57–66. [PubMed]
  • Yung AR, Yuen HP, Berger G, Francey S, Hung TC, Nelson B, Phillips L, McGorry P. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull. 2007;33 (3):673–681. [PMC free article] [PubMed]
  • Yung AR, Nelson B, Stanford C, Simmons MB, Cosgrave EM, Killackey E, Phillips LJ, Bechdolf A, Buckby J, McGorry PD. Validation of “prodromal” criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res. 2008;105 (1–3):10–17. [PubMed]
  • Yung AR, Nelson B, Thompson AD, Wood SJ. Should a “risk syndrome for psychosis” be included in the DSMV? Schizophr Res. 2010;120 (1–3):7–15. [PubMed]